| INTRODUC TI ON
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder estimated to affect up to 20% of adults in the US population, with the diarrhea subtype (IBS-D) experienced by approximately 40% of patients with IBS.
1,2 IBS-D is characterized by recurring abdominal pain associated with loose, frequent stools in the absence of demonstrable organic disease. [3] [4] [5] While abdominal pain and diarrhea are the cardinal symptoms of IBS-D, patients may experience a broad range of abdominal and bowel symptoms, [6] [7] [8] including abdominal bloating and distention, 7 unpredictable bowel patterns involving both form and frequency, and fecal urgency and incontinence. 6, 7, 9 Symptoms such as bloating and urgency are common in IBS-D and may be extremely bothersome, greatly impacting patients' daily lives. In a survey including 1001 patients with IBS-D, loss of bowel control or fecal incontinence was reported as the most bothersome symptom. 10 Symptoms of IBS-D can range from mild and intermittent to more severe and continuous, with abdominal pain and bloating being strongly related to perceived disease severity. 11, 12 Traditionally, pharmacologic management has primarily involved addressing specific symptoms, with limited evidence that many existing treatments effectively control the multiple symptoms of IBS-D. 13 In one study, more than half of patients with IBS-D reported inadequate symptom control with the currently available medication options. 14 IBS-D is associated with a substantial economic burden in terms of its impact on work productivity and healthcare resource use, and patients with inadequate symptom control use significantly more healthcare resources and incur significantly greater costs. 14, 15 Eluxadoline, a mixed μ-and κ-opioid receptor agonist and δ-opioid receptor antagonist approved for the treatment of IBS-D in adults, 16 has demonstrated efficacy for multiple IBS-D symptoms, based on 2 large Phase 3 trials. Significantly greater proportions of patients receiving eluxadoline were responders vs placebo based on a primary composite endpoint consisting of simultaneous reduction in abdominal pain and improvement in stool consistency. 17 Further analyses demonstrated sustained benefits in patients with IBS-D, as more than two-thirds of patients who were composite or adequate relief responders with eluxadoline over the first month of therapy retained their response throughout 6 months of treatment. 18 Furthermore, multiple secondary endpoints were improved across both trials. 
Measurement of treatment effects in IBS is
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We report data from the 2 Phase 3 studies of eluxadoline and utilize radar plots to present the wide range of efficacy measures assessed and address the spectrum of symptoms experienced by patients with IBS-D in 2 simple graphical representations. 
| MATERIAL S AND ME THODS
| Study design
| Study assessments
Participants recorded daily and weekly assessments of IBS-D symptoms and bowel function using an electronic diary with an interactive voice response system. 17 
| Patient population
The studies enrolled patients aged 18-80 years meeting the Rome III criteria for IBS-D. 17, 26 During the week prior to randomization, eligible patients were required to report an average worst abdomi- 
| Efficacy endpoints
As previously reported, 17 the primary efficacy endpoint of both studies was composite response defined as daily improvement of ≥30% in worst abdominal pain score vs average baseline pain and, on the same day, a BSFS score of <5 or the absence of a bowel movement if accompanied by an improvement of ≥30% in abdominal pain score, on ≥50% of treatment days. Abdominal pain response was defined as daily improvement of ≥30%, ≥40%, or ≥50% vs average baseline pain for ≥50% of days with diary entries. Stool consistency response was defined as a BSFS score of <5 on ≥50% of treatment days, or the absence of a bowel movement if accompanied by an improvement of ≥30% in abdominal pain score. Adequate relief response was defined as a weekly "yes" response for ≥50% of treatment weeks. Urgency-free responders were calculated using criteria of ≥50% or ≥75% of days with no diary entry of urgency episodes.
Response rates were evaluated over 26 weeks, requiring a minimum of 110 diary-entry days for a patient to be considered as a responder.
Additionally, changes from baseline to Week 26 in IBS-D GSS, abdominal discomfort, abdominal pain, abdominal bloating, and number of bowel movements were assessed.
| Data analyses
Statistical analyses for the Phase 3 trials have been described previously. 17 In brief, efficacy data from the 2 Phase 3 studies were pooled, with analyses performed on the intent-to-treat analysis set.
No imputation for missing data was performed, as diary compliance rules accounted for absent diary entries. Patients with insufficient diary data were categorized as non-responders.
| Generation of radar plots
Response 
| RE SULTS
| Baseline demographics and disease characteristics
Across both studies, 2428 patients were enrolled (1282 in IBS-3001;
1146 in IBS-3002). Patient demographics and baseline characteristics were balanced between the 2 individual studies and across treatment groups. 17 Mean age (SD) was 44.9 (13.7) in IBS-3001 and 45.9 (13.5) in IBS-3002, with a greater proportion of female patients in both studies (IBS-3001: 65.4%; IBS-3002: 67.0%). In the pooled Phase 3 population, baseline disease characteristics were similar between treatment groups (Table 1) . Patients receiving eluxadoline also reported improved bowel movement frequency, with a daily mean number of bowel movements decrease of 2.0 for both eluxadoline 75 mg (n = 515) and 100 mg (n = 528) vs a decrease of 1.6 with placebo (n = 526).
| Proportions of responders over Weeks 1-26 in the pooled
| D ISCUSS I ON
Presentation of pooled efficacy data from 2 large Phase 3 studies in radar plots demonstrates that eluxadoline treatment offers is variable. 8, 13, 29, 30 The data presented in this study, therefore, suggest that eluxadoline provides a valuable new option for the management of IBS-D.
F I G U R E 1 Weeks 1-26 responder rates for composite endpoint, stool consistency, urgency-free days, adequate relief, and pain with eluxadoline 75 and 100 mg vs placebo: pooled Phase 3 population. Stool consistency score was reported on a 7-point scale, where 1 indicates hard stool and 7 indicates watery diarrhea; abdominal pain score was reported on an 11-point scale, where 0 indicates no pain and 10 indicates worst pain imaginable. Patients were asked to record the number of urgency episodes daily over the past 24 hours. Composite response was defined as daily improvement of ≥30% in worst abdominal pain score vs average baseline pain and, on the same day, a Bristol Stool Form Scale score of <5 on ≥50% of treatment days. 17 Stool consistency response was defined as for the composite response. Urgencyfree responders were calculated using criteria of ≥50% or ≥75% of days with no diary entry of urgency episodes. Adequate relief response was defined as a weekly "yes" response to the following question: "Over the past week, have you had adequate relief of your irritable bowel syndrome symptoms?" on ≥50% of treatment weeks. Pain response was defined as daily improvement of ≥30%, ≥40%, or ≥50% in worst abdominal pain score vs average baseline pain on ≥50% of treatment days. a Data reported in Lembo et al. 2016 . 
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